News Breaks |
|
|
| March 4, 2013 |
| 10:57 EDT |  | GSK, CBST, MITK, CWH, SSYS | High option volume stocks: GSK CBST MITK CWH SSYS
|
|
|
News For GSK;CBST;MITK;CWH;SSYS From The Last 14 Days Check below for free stories on GSK;CBST;MITK;CWH;SSYS the last two weeks. |
|
|
| June 18, 2013 |
| 08:37 EDT |  | GSK | Drug companies turn to microchips to test medicines, WSJ reports
 Subscribe for More Information |
|
| 07:13 EDT |  | GSK | Aspen in talks buy GSK's Arixtra, Fraxiparine brands
Subscribe for More Information |
|
| 07:07 EDT | | GSK | GlaxoSmithKline receives offer for thrombosis brands from Aspen
GlaxoSmithKline said it received an offer for its thrombosis brands and Notre-Dame de Bondeville site from Aspen Global. A period of exclusivity has been agreed with Aspen. The financial terms are confidential at this time, but the offer includes the transfer of the Arixtra and Fraxiparine brands to Aspen, along with the related manufacturing site and the majority of employees at NDB in France and certain dedicated commercial employees, GSK said. "The proposed transaction is aligned to GSK's strategy of focusing on products with the most growth potential and the delivery of its pipeline," the company added. |
|
| June 17, 2013 |
| 10:39 EDT | | CWH | CommonWealth REIT urges shareholders to take no action to Corvex solicitation
Subscribe for More Information |
|
| 09:03 EDT | | CWH | Corvex and Related expresses "unacceptable value" for Commonwealth REIT
Subscribe for More Information |
|
| June 14, 2013 |
| 13:11 EDT | | CWH | Marcato Capital urges removal of CommonWealth board
Marcato Capital, a San Francisco-based investment manager that holds approximately 3.7M common shares or approximately 3.1% of the common shares outstanding of CommonWealth REIT, sent a letter to CommonWealth’s independent trustees. In its letter, Marcato agreed with ISS' recommendation that shareholders vote in favor of the removal of the current board. |
|
| 12:05 EDT | | CWH | CommonWealth REIT comments on ISS report
CommonWealth REIT issued the following statement in response to a recent report from Institutional Shareholder Services regarding the purported written consent solicitation by Corvex Management, Related Fund Management, and others to remove without cause all of the members of CommonWealth's Board: "The Company strongly believes that it is not appropriate for ISS to issue any report or recommendation at this time, as no valid record date has been set and the Corvex/Related activities do not constitute a valid consent solicitation. The validity of the Corvex/Related consent solicitation depends upon a court or an arbitration panel making a number of findings, including that certain of CommonWealth's bylaws are invalid and that its Board members may be removed without cause. The company is also disappointed that ISS issued this report before it is appropriate to do so because it will likely cause confusion among CommonWealth shareholders." The company urges shareholders to ignore the premature recommendation issued by ISS and discard any materials they may have received from Corvex/Related. There is no valid consent solicitation underway and no action is necessary - or even possible - for CommonWealth shareholders to take at this time. |
|
| June 13, 2013 |
| 13:33 EDT | | SSYS | 3D printer makers rise after analyst says demand looks strong
Subscribe for More Information |
|
| 08:32 EDT | | CBST | Cubist names Dr. Lorianne Masuoka Chief Medical Officer
Subscribe for More Information |
|
| 07:02 EDT |  | SSYS | Piper sees another favorable earnings season for 3D printers
Subscribe for More Information |
| |
| June 12, 2013 |
| 19:54 EDT | | GSK | GlaxoSmithKline investigates bribe claims in China, WSJ says
Subscribe for More Information |
|
| 07:16 EDT | | GSK | GlaxoSmithKline fires head of R&D in China, WSJ says
GlaxoSmithKline has fired it's head of R&D in China after finding that he had incorporated "misinterpreted" data in a paper he helped write for a journal, Nature Medicine, according to The Wall Street Journal, citing the company. Reference Link |
|
| June 6, 2013 |
| 15:59 EDT | | GSK | FDA votes for modified restrictions on GSK's Avandia, Reuters says
Subscribe for More Information |
|
| 15:42 EDT | | GSK | FDA panel revote reaffirms modified restrictions for GSK's Avandia, Reuters says
|
|
| 15:26 EDT | | GSK | FDA advisers say Glaxo Avandia vote may have been inaccurate, Bloomberg says
Advisers plan to take a break to assess problem with vote tally and plan to re-vote on GSK's Avandia after break, Bloomberg says. |
|
| 15:20 EDT | | GSK | FDA panel votes to modify market restrictions for Avandia, Reuters says
Subscribe for More Information |
|
| June 5, 2013 |
| 07:45 EDT |  | GSK | FDA to host a joint committee meeting
Joint Meeting of the Endocrinilogic & Metabolic Drugs Advisory Committee and the Drug Safety & Risk Management Advisory Committee where the discussion on both days will be on GlaxoSmithKline's New Drug Application (NDA) 21071 for AVANDIA (Rosiglitazone Maleate) tablets is being held in FDA Offices in Silver Spring, Maryland on June 5-6 beginning at 8 am. Webcast Link |
|
| June 4, 2013 |
| 07:06 EDT | | GSK | Response Genetics achieves milestone payments totaling $1M from GlaxoSmithKline
Subscribe for More Information |
|
|
|
|
|
